{
  "id": "6417949d690f196b51000035",
  "type": "list",
  "question": "Which gene therapies are under investigation for Duchenne muscular dystrophy?",
  "ideal_answer": "Gene therapies under investigation for Duchenne muscular dystrophy include exon skipping, stop codon read-through, gene editing, and gene replacement.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/23387802",
    "http://www.ncbi.nlm.nih.gov/pubmed/22846203",
    "http://www.ncbi.nlm.nih.gov/pubmed/12206797",
    "http://www.ncbi.nlm.nih.gov/pubmed/17217326",
    "http://www.ncbi.nlm.nih.gov/pubmed/20041827",
    "http://www.ncbi.nlm.nih.gov/pubmed/18228186",
    "http://www.ncbi.nlm.nih.gov/pubmed/12206800",
    "http://www.ncbi.nlm.nih.gov/pubmed/22892952",
    "http://www.ncbi.nlm.nih.gov/pubmed/31603849",
    "http://www.ncbi.nlm.nih.gov/pubmed/23328943",
    "http://www.ncbi.nlm.nih.gov/pubmed/19527108",
    "http://www.ncbi.nlm.nih.gov/pubmed/29351004",
    "http://www.ncbi.nlm.nih.gov/pubmed/26140505",
    "http://www.ncbi.nlm.nih.gov/pubmed/19555515",
    "http://www.ncbi.nlm.nih.gov/pubmed/20150322",
    "http://www.ncbi.nlm.nih.gov/pubmed/23609411",
    "http://www.ncbi.nlm.nih.gov/pubmed/34175043",
    "http://www.ncbi.nlm.nih.gov/pubmed/17846262",
    "http://www.ncbi.nlm.nih.gov/pubmed/30414046"
  ],
  "snippets": [
    {
      "text": " In relation to clinical trials, in the last ten years, has experienced great advances in the field of therapeutic options, divided into two major therapeutic targets: 1) the area of gene therapies and 2) trying to reverse or block the pathophysiological processes of the disease, such as inflammation, fibrosis, muscle regeneration, etc. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31603849",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Several promising gene therapies are currently under investigation. These include gene replacement, exon skipping, suppression of stop codons.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29351004",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "More recently, a promising gene editing tool referred to as CRISPR/Cas9 offers exciting perspectives for restoring dystrophin expression in patients with DMD.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29351004",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Adeno-associated virus-vectorized gene therapies to restore dystrophin protein expression using gene replacement or antisense oligonucleotide-mediated pre-mRNA splicing modulation have emerged, making great strides in uncovering barriers to gene therapies for DMD and other genetic diseases",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34175043",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We recently showed that antisense oligoribonucleotide-mediated skipping of exon 46 efficiently induced dystrophin synthesis in cultured muscle cells from Duchenne muscular dystrophy patients carrying an exon 45 deletion.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12206800",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The success of induced exon skipping has spawned a number of \"fusion therapies\", including vector-mediated dystrophin exon skipping and ex vivo viral delivery of splice-switching antisense molecules into myogenic stem cells, followed by implantation, which may address long term oligomer delivery issues.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20041827",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Several clinical trials have recently demonstrated that oligonucleotide-based drugs induced targeted exon skipping in dystrophin pre-mRNA in Duchenne muscular dystrophy patients, resulting in novel expression of a truncated but functional isoform of the dystrophin protein.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22846203",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "These strategies include gene replacement with adeno-associated virus, exon skipping with antisense oligonucleotides, and mutation suppression with compounds that \"read through\" stop codon mutations.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23328943",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "There are several promising genetic approaches, including viral delivery of the missing dystrophin gene, read-through of translation stop codons, exon skipping to restore the reading frame and increased expression of the compensatory utrophin gene.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23609411",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "So far, there is no effective treatment but new gene-based therapies are currently being developed with particular noted advances in using conventional gene replacement strategies, RNA-based approaches, or cell-based gene therapy with a main focus on Duchenne muscular dystrophy (DMD).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19527108",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Myodys, a full-length dystrophin plasmid vector for Duchenne and Becker muscular dystrophy gene therapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18228186",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "The first viral-mediated gene transfer for any muscle disease was carried out at Columbus Children's Research Institute and Ohio State University for limb girdle muscular dystrophy type 2D, and the first viral-mediated trial of gene transfer for Duchenne muscular dystrophy is under way at the same institutions.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17846262",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Adeno-associated virus-vectorized gene therapies to restore dystrophin protein expression using gene replacement or antisense oligonucleotide-mediated pre-mRNA splicing modulation have emerged, making great strides in uncovering barriers to gene therapies for DMD and other genetic diseases.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34175043",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Of all novel molecular interventions currently being investigated for Duchenne muscular dystrophy, perhaps the most promising method aiming to restore dystrophin expression to diseased cells is known as 'exon skipping' or splice-modulation, whereby antisense oligonucleotides eliminate the deleterious effects of DMD mutations by modulating dystrophin pre-messenger RNA splicing, such that functional dystrophin protein is produced.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20150322",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12206800",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Several new approaches to gene therapy for the muscular dystrophies involve oligonucleotides as targeting vectors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12206797",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "gene therapy, an approach that demonstrates promise for treating Duchenne muscular dystrophy. Gene therapy is not limited to replacement of defective genes but also includes strategies using surrogate genes with alternative but effective means of improving cellular function or repairing gene mutations",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17846262",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "rophy gene which abort dystrophin synthesis. We have explored a gene correction therapy aimed at restoration of the reading frame in Duchenne muscular",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12206800",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "on gene replacement and gene/expression repair, including exon-skipping, vector-mediated gene therapy and cell therapy. Therapeutic strategies for different forms of muscular dystrophy are discussed, with an emphasis on ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23387802",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "gene replacement, exon skipping, suppression of stop codons, CRISPR/Cas9, Adeno-associated virus-vectorized gene therapies to restore dystrophin protein expression"
}